JonesResearch downgraded Korro Bio (KRRO) to Hold from Buy without a price target after the company announced KRRO-110 did not reach target levels of functional alpha-1 antitrypsin. The firm cites the stock’s lack of near-term catalysts and failure to demonstrate proof-of-concept for its RNA editing platform for the downgrade.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO: